No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long-term ublituximab (UBL) treatment in patients with relapsing Multiple Sclerosis (RMS) By admin / 04/07/2025
ENABLE: the first phase 4 observational study for patients with relapsing MS treated with ublituximab in real world clinical settings By admin / 04/07/2025
Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-World Observational Survey (ENAMOR) By admin / 04/07/2025
Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series By admin / 04/03/2025
The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function By admin / 04/03/2025
Safety and Tolerability of 30-minute Ublituximab Infusions: Updates from the ENHANCE Study By admin / 02/27/2025
The Design of a Study to Evaluate Fc Biology and Genetic Diversity in Multiple Sclerosis By admin / 02/27/2025
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis By admin / 10/23/2024
Comparison of Multiple Sclerosis Disease Activity (MSDA) Test Results Between Patients Treated with Ublituximab and Teriflunomide in the Phase 3 ULTIMATE I and II Studies By admin / 09/18/2024
Five Years of Ublituximab in Relapsing Multiple Sclerosis: Results from the Open-Label Extension of ULTIMATE I and II Studies By admin / 09/18/2024
